Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells
Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells
Shoreline Biosciences Announces Appointment of Mauro P. Avanzi, M.D., Ph.D., As Chief Medical Officer
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a
BioWorld Insider Podcast: One-on-one with Medical Innovators
Another record year for biopharma financings bodes well for 2022 Listen to the podcast! In another record year for biopharma fundraisings, more money than ever
BioWorld Insider Podcast: One-on-one with Medical Innovators
Another record year for biopharma financings bodes well for 2022 https://www.bioworld.com/ext/resources/Podcast-files/bioworld_ep12_061221_edit2.mp3?1639088948 In another record year for biopharma fundraisings, more money than ever pulsed through the
Harnessing the body’s natural killers to target cancer
Natural killer cells, the body’s first line of defence against emerging cancers, could be engineered into powerful, off-the-shelf cancer therapies. Natural killer (NK) cells are
Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing
CEO Kleanthis Xanthopoulos touts the San Diego biotech’s engineering prowess in developing iPSC-derived NK cells and macrophages against cancerBy Alex Philippidis November 8, 2021 Shoreline
California Life Sciences awarded Kite Pharma, a Gilead company, and Shoreline Biosciences the 2021 Strategic Partnership of the Year Award
https://shorelinebio.com//wp-content/uploads/2021/11/CA-Life-Sciences-Pantheon-Awards-2021.mov Shoreline Biosciences, Inc. is thrilled and honored to be recognized by the California Life Sciences (CLS) as the #Pantheon2021 award winner for the Strategic Partnership of the Year Award.
Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells
SAN DIEGO, March 16, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells
SAN DIEGO, March 16, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences Announces Appointment of Mauro P. Avanzi, M.D., Ph.D., As Chief Medical Officer
SAN DIEGO, Feb. 21, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and
Shoreline Biosciences Announces Oral Presentation on Novel Manufacturing Method of Ink Cells at The 64th American Society of Hematology (ASH) 2022 Meeting
SAN DIEGO, Dec. 5, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences Announces Appointment of Cell Therapy Manufacturing Veteran Charles Calderaro III as Chief Technical Officer
SAN DIEGO, Oct. 24, 2022 / — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing